The Week Ahead: Hom...
Health Care: Drugs
Merrimack Pharmaceuticals Inc (MACK: NASDAQ)
$5.52 0.04 | 0.73%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | ||
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -91.75M | -79.68M | -50.16M | |
| Operating Gains/Losses | 0.00 | 864.00K | -130.00K | |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | |
| (Increase) Decrease In Receivables | -1.84M | -3.68M | -1.98M | |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | |
| (Increase) Decrease In Other Current Assets | -2.35M | 0.00 | 0.00 | |
| (Decrease) Increase In Payables | 6.98M | 3.22M | -830.00K | |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 5.60M | 1.02M | |
| (Increase) Decrease In Other Working Capital | 1.58M | 13.25M | 14.42M | |
| Other Non-Cash Items | 6.38M | 6.95M | 8.22M | |
| Net Cash From Continuing Operations | -79.82M | -52.82M | -26.37M | |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -79.82M | -52.82M | -26.37M | |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 26.00K | |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | |
| Purchases of Property, Plant & Equipment | -3.19M | -3.75M | -5.02M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | |
| Other Cash from Investing Activities | -247.00K | 7.00K | 99.00K | |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -75.22M | -3.75M | -4.90M | |
| Issuance of Debt | 41.13M | 0.00 | 0.00 | |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 105.45M | 78.69M | 4.46M | |
| Repayment of Long-Term Debt | -48.00K | -443.00K | -864.00K | |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | |
| Payment of Cash Dividends | -4.24M | 0.00 | 0.00 | |
| Other Financing Charges, Net | 0.00 | -1.95M | 0.00 | |
| Net Cash From Financing Activities | 142.30M | 76.30M | 3.60M | |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | |
| Net Change in Cash & Cash Equivalents | -12.74M | 19.74M | -27.67M | |
Portfolios with MACK
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks With Big Insider Buy...
- ProTPG-Axon Capital
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
Latest MACK Headlines from TheStreet
- Merrimack Pharmaceuticals Completes Enrollment Of One Cohort In Neoadjuvant Phase 2 Study Of MM-121 In HER2-Negative Breast Cancer 04.15.13 | 08:04 am
- Merrimack Pharmaceuticals Announces Webcast Of Inaugural Research & Development Day 04.05.13 | 12:04 pm
- Merrimack Pharmaceuticals Completes Enrollment In A Phase 2 Study Of MM-121 In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers 03.18.13 | 08:03 am
- Merrimack Reports Fourth Quarter And Full Year 2012 Financial Results 03.14.13 | 08:03 am
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- Merrimack Pharmaceuticals Announces Timing Of Fourth Quarter 2012 Investor Conference Call 02.27.13 | 09:02 am
- Merrimack To Present At The Cowen And Company 33rd Annual Health Care Conference 02.25.13 | 12:02 pm
- Merrimack To Participate In Pancreatic Cancer Panel At The 2013 BIO CEO & Investor Conference 02.07.13 | 12:02 pm
- Merrimack Pharmaceuticals To Present Preclinical Data On Bispecific Antibody MM-111 In ErbB2-Positive Gastric Cancers 01.23.13 | 08:01 am
- Merrimack Pharmaceuticals Initiates Cross-Tumor Study To Investigate Potential Predictive Response Markers For A Developmental Nanotherapeutic Chemotherapy 12.19.12 | 02:12 pm
Press Releases for MACK
- Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model - PR Newswire 04.10.13 | 09:04 am
- Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor - PR Newswire 04.04.13 | 08:04 am
- Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies - PR Newswire 04.02.13 | 09:04 am
- Merrimack Pharmaceuticals Presents Promising Phase I Clinical Data For Novel Agent To Treat HER2-positive Breast Cancer And Preclinical Data On Companion Diagnostic - PR Newswire 12.10.12 | 09:12 am
- Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer - PR Newswire 11.27.12 | 09:11 am
- Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers - PR Newswire 10.02.12 | 08:10 am
- Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers - PR Newswire 09.18.12 | 11:09 am
- Merrimack Pharmaceuticals, Inc. Announces Pricing Of Initial Public Offering - PR Newswire 03.28.12 | 11:03 pm
Partner Headlines for MACK
- After Hours Most Active for Nov 16, 2012 : SFD, QQQ, WIN, TSN, MSFT, TSS, BAC, MYL, ZGNX, WM, MACK, MMC - NASDAQ 11.16.12 | 09:11 pm
- Morning Market Losers - Benzinga 09.25.12 | 09:09 am
- 5 Low-Debt Biotech Stocks Forecasted For Growth - Seeking Alpha 09.22.12 | 09:09 am
- Jim Cramer Watchdog: SELL Morgan Stanley and 'BUY, BUY, BUY' These 3 HOT Stocks - Wall St. Cheat Sheet 07.20.12 | 11:07 am
